Multiple sclerosis (MS) is the most widespread disabling neurological condition among young adults all around the world. You can develop MS at any age, but most people are diagnosed between the ages of 20 and 40.
The Multiple Sclerosis Foundation estimates that more than 400,000 people in the United States and about 2.5 million people around the world suffer from MS.
Magnetic resonance imaging (MRI) of the brain is useful in the diagnosis and treatment of Multiple Sclerosis, an inflammatory, demyelinating condition of the central nervous system (CNS) that is generally considered to be autoimmune in nature. MRI provides reliable detection and quantitative estimation of focal white matter lesions in vivo. Diagnosis of MS is based not only on the disease dissemination in space and time but also on excluding other disorders that can mimic multiple sclerosis. Neurological impairment of MS patients is poorly associated with the lesion load observed on conventional MRI scans, partly due to the low sensitivity of conventional MRI in detecting both grey and white-matter damage.
Mew MRI techniques have been developed in order to overcome these limitations.
Check Dr. Pablo Villoslada’s (professor at UCSF School of Medicine and senior researcher at IDIBAPS, Hospital Clinic, Barcelona) view on this disease, and how he thinks MRI technology can help accelerate the treatment for Multiple Sclerosis.